New medical technologies hold tremendous promise for improving population health, but they also raise concerns about exacerbating already large differences in health by socioeconomic status (SES) (James P. Smith, 1999) . In prior work, we found that better self-management of disease by the more educated was a critical factor in maintaining the SES health gradient for two distinct diseases-diabetes and HIV (Dana Goldman and James P. Smith, 2002) . For these diseases-both characterized by the introduction of new effective treatment technologiesdifferences by education in patient adherence to prescribed treatment explained a significant component of the health gradient.
The impact of a new technology on health disparities depends not only on how difficult it is to adhere, but also on who actually receives the treatment. If effective technologies are more rapidly adopted by the better educated, SES health disparities may initially expand even though the health of those in the lowest SES groups eventually improves.
Hypertension provides a useful example. It is a major risk factor for cardiovascular disease and a relatively common condition-in 2002, 21% of those 18 and older had the disease, and the prevalence grows rapidly with age (over 50% among those 65 and over). There also is a gradient with schooling-29% prevalence among those with less than a high school diploma compared to only 19% for those with a bachelor's degree or more.
1 Before the introduction of effective drugs, the recommended treatment consisted of some combination of exercise and diet, particularly to reduce excessive weight and salt. But as a consequence of positive results from clinical trials, starting in the early 1970s, a sequence of very effective drug treatments has been introduced.
In this paper, we examine the short and long-term diffusion of anti-hypertensive therapy and how that diffusion varies by a key SES marker-education. The data in Table 1 inform us that the use of drugs to treat hypertension has grown rapidly over these sixteen years and is no doubt a key factor contributing to the substantial decline in heart disease risk and mortality. This expansion partly reflects the increased use of existing drugs, but also the adoption of a series of new drug innovations hitting the market.
Following FDA approval for hypertension in 1976, beta-blockers were introduced into widespread clinical practice; by 1978, 10% of the Framingham hypertensives were using the drug. Usage rate doubled over the next four years and plateaued around 30% by the late 1980s.
FHS first asked about calcium channel blockers in 1982, but their use received a big boost when they were recommended by a national panel of experts in 1988 as an option for first line therapy (JNC IV, 1988) . Finally, ACE inhibitors first appear in the FHS in 1986 and were quickly adopted in the late 1980s and early 1990s. These last two drugs in particular appear to both expand overall drug use but also to substitute to some extent for older antihypertensives.
Our principal question concerns the relative speed of adoption of these new drug therapies of people with different education levels. These patterns are described in Table 2 . Is it the case that more educated patients adopt new drugs at a more rapid rate? The two most interesting drugs for our purposes are calcium channel blockers and ACE inhibitors, since we can observe the full adoption paths. For neither of them do there appear to be any systematic differences by schooling in the speed of adoption.
As a more formal test, using the FHS we estimated linear regression models for the use of each drug where the covariates included age, gender, marital status, the education classes used in 1988-1991 and 1991-1994) .
We estimated models predicting the use of calcium channel blockers and ACE inhibitors for people with hypertension. These models included measures of the demographic variables listed above, health co-morbidities (serum cholesterol, serum glucose, diabetes, arthritis, bronchitis, asthma, cancer, and heart disease) and health behaviors (smoking). For our purpose, the critical variables are household income and individual education (classified as not a high school graduate, high school grad, and more than high school). Household income was never statistically significant, and the p-values for the F-tests for education were 0.65 for channel betablockers and 0.45 for ACE inhibitors. The results for these SES variables did not change if we limited the sample to those hypertensives taking medication or to the first phase of NHANES III (spanning 1988 to 1991 only). These models also included mean level of education in the identifiable areas. In no case was area-specific, mean education levels related to the adoption of any of the drugs, providing additional evidence that a relationship between education and adoption emerges as more educated areas adopted more quickly.
Conclusions
The reasons for the very large difference in health outcomes by several measures of SES are being vigorously debated anew within and outside economics (Smith, 2005) . In this paper, we investigated one possible reason for the health gradient-that novel and effective medical technologies are adopted more quickly by those with higher SES, giving them at least a temporary advantage in improved health. We test this hypothesis by examining the introduction of new drugs to treat hypertension, of which there have been several important examples over the last twenty-five years. However, using three prominent medical surveys we find no evidence that the diffusion of these drugs into medical treatment favored one education group relative to
another. This suggests that at least for hypertension, a key risk factor for heart disease, the SES differences in the adoption of new medical technologies are not an important reason for the SES health gradient.
There are several caveats to our conclusions. We have only analyzed a single medical condition, one where the short-term medical risks are not great, the recommended drug therapies not particularly expensive, and where the therapeutic efficacy of some of the new drug innovations has been questioned ex post. Whether our findings reported here extend to other diseases, especially those that are more severe and/or more expensive to treat so that people with higher incomes may have an extra advantage, must await additional research by others and us. 1978 1980 1982 1984 1986 1988 1990 1992 1994 8 1 9 8 1 1 9 8 5 1 9 8 9 1 9 9 0 1 9 9 1 1 9 9 2 1 9 9 3 1 9 9 4 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 2 0 0 1 Year
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